

24 July 2023

Oesophageal and Gastric Cancer

1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- Lonsurf (Trifluridine - tipiracil)
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Response in table below question 2.

2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only - Information not held on Regional Information System for Oncology and Haematology (RISOH).

Response in table below:

Oesophageal		Gastric		OG	
CarboX with XRT	7	CX	<5	CX + Trazimera	27
CX + XRT	13	Docetaxel	7	Nivolumab OMDG (FOLFOX)	<5
CX	17	FLOT	90	OMDG (FOLFOX)	18
Docetaxel	<5	IMDG (FOLFIRI)	<5	OX + Trazimere	15
EOX 4	<5	Nivolumab	<5	OX	22
IMDG (FOLFIRI)	25			Pembrolizumab	<5
Nivolumab	26			Pembrolizumab CX	13
Weekly Cisplatin + XRT	<5			Pembrolizumab OX	19
Weekly Paclitaxel + Carboplatin + XRT	13				

24 July 2023

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

3. How many patients were treated in the past 3 months for advanced / metastatic resected oesophageal cancer ONLY with:

- Nivolumab monotherapy or combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Information not held on Regional Information System for Oncology and Haematology (RISOH).

4. In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

- Nivolumab monotherapy or in combination with Ipilimumab 6
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) <5

We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable.

24 July 2023

5. Does your Trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.

Gastric Cancer Trials

Studies open to recruitment				
Title acronym	Full Title	Date Study Opened	Planned recruitment end date	TOTAL study recruitment
ADD-ASPIRIN (with GI cohort)	A phase III double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non metastatic solid tumours.	01/11/2017	Q2 2025	6 (GI cohort)
PLATFORM	Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial	06/06/2019	31/03/2025	<5 recruited (1 randomised)
ICHOR	Investigation of Circulating Haematological Biomarkers in cancer	01/08/2019	31/05/2025	24

Studies in set-up	
Title acronym	Full Title
DECIPHER	A single arm phase II trial of Trastuzumab Deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA & HER2-positive.
DESTINY-04	A Phase 3 multi-centre, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects who have progressed on or after a Trastuzumab-containing regimen
SARONG	Open label randomised controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer

We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable.

24 July 2023

6. Does your Trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

Oesophageal Cancer Trials:

Studies open to recruitment				
Title acronym	Full Title	Date Study Opened	Planned recruitment end date	TOTAL study recruitment
ADD-ASPIRIN (with GI cohort)	A phase III double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non metastatic solid tumours.	01/11/2017	Q2 2025	6 (GI cohort)
PLATFORM	Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial	06/06/2019	31/03/2025	<5 recruited (1 randomised)
SCOPE 2	A randomised Phase II/III trial to	21/01/2019	31/12/2023	11
ICHOR	Investigation of Circulating Haematological Biomarkers in cancer	01/08/2019	31/05/2025	24

Studies in set-up	
Title acronym	Full Title
DECIPHER	A single arm phase II trial of Trastuzumab Deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA & HER2-positive.
DESTINY-04	A Phase 3 multi-centre, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in subjects with HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma subjects who have progressed on or after a Trastuzumab-containing regimen
SARONG	Open label randomised controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer

We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act as this could make patients personally identifiable